Guillain-Barré Syndrome (Campylobacter jejuni)
Overview
Plain-Language Overview
Guillain-Barré Syndrome (GBS) is a rare disorder where the body's immune system mistakenly attacks the nerves. It mainly affects the peripheral nervous system, which controls muscle movement and sensation. This condition often starts with weakness and tingling in the legs that can spread to the upper body. Many cases of GBS occur after an infection, especially with the bacteria Campylobacter jejuni. The nerve damage can cause muscle weakness, difficulty walking, and sometimes problems with breathing. Recovery can take weeks to months, and some people may have lasting effects. Early recognition of symptoms is important because the condition can progress rapidly.
Clinical Definition
Guillain-Barré Syndrome (GBS) is an acute, immune-mediated polyneuropathy characterized by demyelination and/or axonal damage of peripheral nerves. It typically follows an infectious trigger, most commonly Campylobacter jejuni, which induces a molecular mimicry autoimmune response against peripheral nerve components such as gangliosides. The hallmark clinical features include progressive, symmetric muscle weakness, areflexia, and sensory disturbances. The syndrome can lead to respiratory failure due to diaphragmatic weakness and autonomic dysfunction. Pathologically, there is infiltration of inflammatory cells and segmental demyelination or axonal degeneration. GBS is a major cause of acute flaccid paralysis worldwide and requires prompt diagnosis and management to prevent morbidity and mortality.
Inciting Event
Antecedent diarrheal illness caused by Campylobacter jejuni infection typically precedes symptom onset by 1-3 weeks.
Upper respiratory tract infections can also trigger the autoimmune response.
Vaccinations have rarely been associated as triggers but are not common causes.
Latency Period
1 to 3 weeks between Campylobacter jejuni infection and onset of neurological symptoms is typical.
Symptom onset usually follows the inciting infection by a latent period allowing immune sensitization.
Diagnostic Delay
Initial symptoms such as distal paresthesias and weakness may be mistaken for viral illness or musculoskeletal pain.
Early presentation with nonspecific symptoms can lead to misdiagnosis as stroke or spinal cord pathology.
Lack of awareness of recent infection history delays consideration of Guillain-Barré syndrome.
Normal early nerve conduction studies may falsely reassure clinicians before demyelination progresses.
Clinical Presentation
Signs & Symptoms
Rapidly progressive symmetric weakness starting in the lower extremities and ascending proximally
Paresthesias or mild sensory symptoms often in distal limbs
Areflexia or hyporeflexia on neurological exam
Autonomic symptoms including orthostatic hypotension, cardiac arrhythmias, and urinary retention
Preceding gastrointestinal illness typically due to Campylobacter jejuni infection
History of Present Illness
Progressive, symmetric ascending weakness starting in the lower limbs and advancing proximally is classic.
Paresthesias and numbness often precede weakness by days.
Areflexia or hyporeflexia develops as motor nerve conduction is impaired.
Autonomic symptoms such as tachycardia, blood pressure fluctuations, and urinary retention may occur.
Respiratory muscle involvement can lead to dyspnea and requires urgent monitoring.
Past Medical History
Recent gastrointestinal or respiratory infection within the past 1-3 weeks is common.
No prior neurological disease is typical before Guillain-Barré syndrome onset.
Immunizations within the preceding weeks may be noted but are rarely causative.
Family History
Guillain-Barré syndrome is generally not inherited and lacks familial clustering.
No known heritable syndromes are associated with increased risk of Guillain-Barré syndrome.
Family history is typically noncontributory in diagnosis.
Physical Exam Findings
Symmetric ascending flaccid paralysis with decreased or absent deep tendon reflexes
Facial diplegia and bulbar muscle weakness may be present
Sensory deficits are mild or absent despite weakness
Autonomic dysfunction including tachycardia, labile blood pressure, and arrhythmias
Diagnostic Workup
Diagnostic Criteria
Diagnosis of Guillain-Barré Syndrome is primarily clinical, based on progressive symmetric weakness of more than one limb and areflexia. Supportive diagnostic findings include elevated cerebrospinal fluid (CSF) protein with normal cell count (albuminocytologic dissociation) and nerve conduction studies showing demyelination or axonal damage. A history of recent infection, especially with Campylobacter jejuni, supports the diagnosis. Other causes of acute weakness must be excluded to confirm the diagnosis.
Pathophysiology
Key Mechanisms
Molecular mimicry between Campylobacter jejuni lipooligosaccharides and peripheral nerve gangliosides triggers an autoimmune response.
Autoantibody production against myelin or axonal components leads to demyelination or axonal damage in peripheral nerves.
Complement activation and macrophage-mediated nerve injury cause conduction block and muscle weakness.
Inflammatory infiltration of peripheral nerves results in segmental demyelination and impaired nerve conduction.
| Involvement | Details |
|---|---|
| Organs | Peripheral nerves are affected by autoimmune demyelination causing ascending weakness and sensory symptoms. |
Respiratory muscles can be involved leading to respiratory failure requiring ventilatory support. | |
| Tissues | Peripheral nerve myelin is the primary target of immune-mediated demyelination in Guillain-Barré syndrome. |
Peripheral nerve axons may be secondarily damaged, contributing to weakness and sensory loss. | |
| Cells | Macrophages mediate demyelination by phagocytosing myelin in peripheral nerves. |
T cells contribute to autoimmune attack against peripheral nerve components. | |
Schwann cells are damaged during demyelination but also participate in nerve repair. | |
| Chemical Mediators | Anti-ganglioside antibodies (e.g., anti-GM1) target peripheral nerve myelin and axons, triggering immune-mediated damage. |
Complement system activation leads to membrane attack complex formation and nerve injury. | |
Cytokines such as TNF-alpha and IL-6 promote inflammation and recruit immune cells to peripheral nerves. |
Treatments
Pharmacological Treatments
Intravenous immunoglobulin (IVIG)
- Mechanism:
Provides pooled antibodies that neutralize pathogenic autoantibodies and modulate immune response.
- Side effects:
Headache
Thrombosis
Renal dysfunction
- Clinical role:
First-line
Plasma exchange (plasmapheresis)
- Mechanism:
Removes circulating autoantibodies and immune complexes from the blood.
- Side effects:
Hypotension
Infection risk
Electrolyte imbalance
- Clinical role:
First-line
Non-pharmacological Treatments
Supportive respiratory care including mechanical ventilation if respiratory muscles are compromised.
Physical therapy to prevent contractures and maintain muscle strength during recovery.
Close monitoring of autonomic function to manage cardiovascular instability.
Prevention
Pharmacological Prevention
No established medication-based prophylaxis for Guillain-Barré syndrome
Avoidance of unnecessary antibiotic use to prevent Campylobacter jejuni infection
Non-pharmacological Prevention
Proper food handling and cooking to reduce Campylobacter jejuni exposure
Hand hygiene to prevent gastrointestinal infections
Avoidance of contaminated water and unpasteurized dairy products
Early treatment of gastrointestinal infections to reduce immune-mediated complications
Outcome & Complications
Complications
Respiratory failure requiring mechanical ventilation
Autonomic instability causing cardiac arrhythmias and blood pressure fluctuations
Deep vein thrombosis and pulmonary embolism due to immobility
Secondary infections including pneumonia and urinary tract infections
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Guillain-Barré Syndrome (Campylobacter jejuni) versus Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Guillain-Barré Syndrome (Campylobacter jejuni) | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
|---|---|
Rapidly progressive weakness reaching nadir within 4 weeks | Progressive or relapsing-remitting weakness over >8 weeks |
Improves with a single course of IVIG or plasmapheresis | Improves with long-term immunosuppressive therapy and repeated IVIG or plasmapheresis |
Marked albuminocytologic dissociation with high CSF protein and normal cell count | Elevated CSF protein with less pronounced albuminocytologic dissociation |
Guillain-Barré Syndrome (Campylobacter jejuni) versus Tick Paralysis
Guillain-Barré Syndrome (Campylobacter jejuni) | Tick Paralysis |
|---|---|
Recent gastrointestinal infection, often with Campylobacter jejuni | Recent tick exposure in endemic area |
Progressive paralysis over days to weeks, requiring immunotherapy | Rapidly ascending paralysis that resolves quickly after tick removal |
Elevated CSF protein with normal cell count (albuminocytologic dissociation) | Normal CSF analysis |
Guillain-Barré Syndrome (Campylobacter jejuni) versus Botulism
Guillain-Barré Syndrome (Campylobacter jejuni) | Botulism |
|---|---|
Ascending symmetric weakness with less prominent cranial nerve involvement | Descending symmetric paralysis with prominent cranial nerve involvement and early autonomic symptoms |
Preceding infection with Campylobacter jejuni or other respiratory/GI infections | Ingestion of contaminated food or wound contamination with Clostridium botulinum spores |
Electrophysiologic studies showing demyelination and elevated CSF protein | Detection of botulinum toxin in serum, stool, or wound |
Guillain-Barré Syndrome (Campylobacter jejuni) versus Acute Transverse Myelitis
Guillain-Barré Syndrome (Campylobacter jejuni) | Acute Transverse Myelitis |
|---|---|
Symmetric ascending motor weakness without a defined sensory level | Bilateral motor, sensory, and autonomic dysfunction below a spinal level with a sensory level |
Normal spinal MRI or nonspecific nerve root enhancement | MRI showing focal spinal cord inflammation and edema |
Albuminocytologic dissociation with elevated protein but normal cell count | CSF pleocytosis with elevated protein |
Guillain-Barré Syndrome (Campylobacter jejuni) versus Myasthenia Gravis
Guillain-Barré Syndrome (Campylobacter jejuni) | Myasthenia Gravis |
|---|---|
Progressive symmetric ascending weakness with areflexia | Fluctuating muscle weakness worsened by activity, primarily affecting ocular and bulbar muscles |
Electrophysiologic evidence of demyelination and elevated CSF protein | Positive acetylcholine receptor or MuSK antibodies |
Improves with IVIG or plasmapheresis | Improves with acetylcholinesterase inhibitors and immunosuppression |